Lü Lingshuang, Mao Xuhua, Shi Peiyi, He Biyu, Xu Kun, Zhang Simin, Wang Jianming
Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing Department of Clinical Laboratory, Yixing People's Hospital, Wuxi Department of Social Medicine and Health Education, School of Public Health, Nanjing Medical University The Innovation Center for Social Risk Governance in Health, Nanjing, China.
Medicine (Baltimore). 2017 Jun;96(22):e7085. doi: 10.1097/MD.0000000000007085.
Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors characterized by their aggressive nature and poor associated survival. MicroRNAs (miRs) have been found to play an important role in the occurrence and development of human cancers, but their role in the prognosis of TNBC patients remains unclear. We performed a meta-analysis to explore the prognostic value of miRs in TNBC.
We systematically searched the PubMed, Embase, and Web of Science databases to identify eligible studies. A meta-analysis was performed to estimate the pooled hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) for the associations between levels of miR expression (predictive factors) and overall survival (OS) and disease-free survival (DFS) (outcomes) in patients with TNBC.
After performing the literature search and review, 21 relevant studies including 2510 subjects were identified. Six miRs (miR-155, miR-21, miR-27a/b, miR-374a/b, miR-210, and miR-454) were assessed in the meta-analysis. Decreased expression of miR-155 was associated with reduced OS (adjusted HR = 0.58, 95% CI: 0.34-0.99; crude HR = 0.67, 95% CI: 0.58-0.79). High miR-21 expression was also predictive of reduced OS (crude HR = 2.50, 95% CI: 1.56-4.01). We found that elevated levels of miR-27a/b, miR-210, and miR-454 expression were associated with shorter OS, while the levels of miR-454 and miR-374a/b expression were associated with DFS.
Specific miRs could serve as potential prognostic biomarkers in TNBC. Due to the limited research available, the clinical application of these findings has yet to be verified.
三阴性乳腺癌（TNBC）是一组异质性肿瘤，其特点是侵袭性强且相关生存率低。微小RNA（miR）已被发现在人类癌症的发生和发展中起重要作用，但其在TNBC患者预后中的作用仍不清楚。我们进行了一项荟萃分析，以探讨miR在TNBC中的预后价值。
我们系统检索了PubMed、Embase和Web of Science数据库，以确定符合条件的研究。进行荟萃分析以估计TNBC患者中miR表达水平（预测因素）与总生存期（OS）和无病生存期（DFS）（结局）之间关联的合并风险比（HR）及其相应的95%置信区间（CI）。
在进行文献检索和综述后，确定了21项相关研究，包括2510名受试者。在荟萃分析中评估了6种miR（miR-155、miR-21、miR-27a/b、miR-374a/b、miR-210和miR-454）。miR-155表达降低与OS降低相关（调整后HR = 0.58，95%CI：0.34 - 0.99；粗HR = 0.67，95%CI：0.58 - 0.79）。高miR-21表达也预示着OS降低（粗HR = 2.50，95%CI：1.56 - 4.01）。我们发现miR-27a/b、miR-210和miR-454表达水平升高与较短的OS相关，而miR-454和miR-374a/b表达水平与DFS相关。
特定的miR可作为TNBC潜在的预后生物标志物。由于现有研究有限，这些发现的临床应用尚待验证。
